Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1

Prevalence and Risk Factors of HIV-associated Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1 Infected Thai Individuals With Undetectable Viral Load in the HAART Era.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00476671

Enrollment

100

Registered

2007-05-22

Start date

2007-03-31

Completion date

2008-06-30

Last updated

2020-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

neuropsychiatric, neurocognitive, psychiatric, HIV related dementia, MCMD, HIV-1, Prevalence, risk factors of neurocognitive impairment and psychiatric comorbidities in HIV-1 infected patients with undetectable viral load in the HAART era., Treatment Experienced

Brief summary

To assess the prevalence and risk factors of neurocognitive impairment and psychiatric comorbidities in HIV infected patients who have undetectable viral load, have been on HAART for at least 1 year and have no history of CNS infection.

Detailed description

To understand how to prevent and treat HIV-associated neurocognitive impairment and psychiatric comorbidities in HIV-infected Thai individuals who don't have current AIDS related illness or current and prior central nervous system (CNS) infection, and have been well treated with HAART with undetectable HIV RNA.

Interventions

PROCEDURElumbar puncture, MRI, MRS

lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed informed consent * Evidence of HIV infection (confirmed positive ELISA and documented history of measurable HIV RNA) * Age \> 18 years old * Plasma HIV RNA of \< 50 copies/ml within 3 months prior to screening * Have been on only NNRTI-based HAART regimen for the entire duration and for at least1 year.

Exclusion criteria

* Current AIDS defining illnesses * Current or history of previous CNS infection. * Head injury with loss of consciousness greater than 1 hour * Acute illness within 30 days prior to entry that, in the opinion of investigators, would prevent patients from completing the protocol required procedures. * Known learning disability including dyslexia

Design outcomes

Primary

Measure	Time frame
Neuropsychological testing score	1 day

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026